• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Cardiovascular Systems shares steady on mixed bag Q1 earnings

Cardiovascular Systems shares steady on mixed bag Q1 earnings

October 26, 2017 By Fink Densford

Cardiovascular Systems

Shares in Cardiovascular Systems (NSDQ:CSII) have risen slightly today after the medical device maker met loss-per-share expectations but missed sales consensus on Wall Street with its first quarter 2018 earnings results.

The St. Paul, Minn.-based company posted losses of $2 million, or 6¢ per share, on sales of $49.7 million for the 3 months ended September 30, seeing losses grow 6.4% while sales shrunk 0.2% compared with the same period during the previous fiscal year.

Losses per share for the quarter came in just ahead of the 7¢ consensus on The Street, while sales fell just short of the Street’s $51 million expectations.

“Fiscal first quarter procedure volumes in two key geographies were impacted by hurricanes during the quarter. In addition, we believe that our saline infusion pump recall resulted in lower coronary device usage during the quarter than anticipated. These factors were key contributors to first quarter revenues being below our guidance. These factors, combined with the complexity of treating severely calcified coronary lesions, have also highlighted some necessary adjustments to our sales model to help drive consistent adoption of our coronary device. As a result, we have reallocated 20 sales representatives to focus exclusively on the coronary opportunity and expanded the number of field sales professionals by 45, primarily by adding clinical specialists. These specialists will increase case coverage and support our sales representatives with both coronary and peripheral customers. We believe these adjustments will enhance sales productivity and drive further adoption in our coronary and peripheral franchises,” chair & CEO Scott Ward said in a press release.

With its earnings release, the company also updated its guidance for the second quarter 2018 and full fiscal year.

For its second quarter, Cardiovascular Systems expects to see revenue between $52.5 million and $54 million with a net loss between $1.9 million and $1 million. Losses per share are expected to be between 6¢ and 3¢.

For the full fiscal year 2018, the company said it expects to post revenue of between $226 and $233 million.

“With the September hurricanes and the pump recall behind us and our sales model adjustments in place, we expect procedure volumes to recover throughout our second quarter and our quarterly revenue growth rates over fiscal year 2017 to improve throughout the year,” Ward said in a prepared statement.

Shares have risen slightly, up 0.5% to $25.51 as of 11:55 a.m. EDT.

Filed Under: Business/Financial News, MassDevice Earnings Roundup Tagged With: Cardiovascular Systems Inc.

More recent news

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy